To include your compound in the COVID-19 Resource Center, submit it here.

Further delays at FDA for Intercept’s NASH therapy

Four months after Intercept disclosed FDA had pushed out the PDUFA date for its non-alcoholic

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE